Mutual of America Capital Management’s Vaxcyte PCVX Stock Holding History

Mutual of America Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-25,270	Closed	-$2.07M	–	1436
2024 Q4	$2.07M	Sell	25,270 -25,071	-50%	-$2.49M	0.02%	842
2024 Q3	$5.75M	Sell	50,341 -472	-0.9%	-$42.5K	0.06%	397
2024 Q2	$3.84M	Buy	50,813 +6,114	+14%	+$416K	0.04%	577
2024 Q1	$3.05M	Sell	44,699 -3,631	-8%	-$251K	0.03%	726
2023 Q4	$3.04M	Buy	+48,330	New	+$2.51M	0.04%	707

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Mutual of America Capital Management's PCVX Position: Q1 2025 in Review

Mutual of America Capital Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 25,270 shares — an estimated $2.07M sold.

Mutual of America Capital Management first reported a position in PCVX in Q4 2023 and held it in 5 quarters. The position peaked at $5.75M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Mutual of America Capital Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Mutual of America Capital Management sold 25,270 Vaxcyte shares in Q1 2025, an estimated $2.07M.
Mutual of America Capital Management first reported a position in Vaxcyte in Q4 2023 and held it in 5 quarters.
Mutual of America Capital Management's Vaxcyte position peaked at $5.75M in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Mutual of America Capital Management's 13F filing for Q1 2025, filed 1 May 2025.